Geraldine M. A. Gillespie

Antibodies against HLA-E-VL9 enhance NK cell and CD8+ T cell cytotoxicity against tumor cells and HIV-infected CD4+ T cells.

Joyce K Hwang, Marina Tuyishime, Daniel J. Marston, Hongbing Yang et autres

T cell function and by promoting ADCC.

us, cn, gb (code pays fourni par la source)

Shared HLA‐E and Mamu‐E Peptide Repertoires With Subtle Peptide Binding Differences Revealed by Combined nDSF‐ and Fluorescence Polarisation‐Based Methods

Max N. Quastel, Sashini A. Ranawana, Bas W. A. Peeters, Andy van Hateren et autres

ABSTRACT The primary function of MHC‐E—human leukocyte antigen (HLA)‐E in humans and Mamu‐E in rhesus macaques—relates to immune surveillance via CD94/NKG2x receptors expressed on NK cells. However, a secondary role where MHC‐E presents immunogenic peptides to CD8 + T cells that provide …

gb (code pays fourni par la source)

A cytoplasmic motif in HLA-E that drives clathrin-mediated endocytosis and VCP-associated postendocytic trafficking

Wanlin He, Andreas Damianou, Iolanda Vendrell, Klaus Früh et autres

Human Leukocyte Antigen E (HLA-E) is a nonclassical MHC class I molecule that exhibits dual immunological functions in regulating natural killer (NK) cells and T cells through unusual trafficking patterns. We previously reported that HLA-E surface expression is low and transient due …

cn, gb, us (code pays fourni par la source)

Targeting MHC-E as a new strategy for vaccines and immunotherapeutics

Klaus Frueh, Persephone Borrow, Geraldine M. A. Gillespie, Andrew James McMichael et autres

us, gb (code pays fourni par la source)

HLA ‐E: Immune Receptor Functional Mechanisms Revealed by Structural Studies

Geraldine M. A. Gillespie, Max N. Quastel, Andrew James McMichael

HLA-E is a nonclassical, nonpolymorphic, class Ib HLA molecule. Its primary function is to present a conserved nonamer peptide, termed VL9, derived from the signal sequence of classical MHC molecules to the NKG2x-CD94 receptors on NK cells and a subset of T …

gb (code pays fourni par la source)

Mucosal signatures of pathogenic T cells in HLA-B*27+ anterior uveitis and axial spondyloarthritis

Michael Paley, Xinbo Yang, Lynn Marisa Hassman, Frank Penkava et autres

HLA-B*27 was one of the first HLA alleles associated with an autoimmune disease, i.e., axial spondyloarthritis (axSpA) and acute anterior uveitis (B27AAU), which cause joint and eye inflammation, respectively. Gastrointestinal inflammation has been suggested as a trigger of axSpA. We recently identified …

us, gb (code pays fourni par la source)

Identification and structural characterization of a mutant KRAS‐G12V specific TCR restricted by HLA‐A3

Malcolm J. W. Sim, Ken‐ichi Hanada, Zachary Stotz, Zhiya Yu et autres

Abstract Mutations in KRAS are some of the most common across multiple cancer types and are thus attractive targets for therapy. Recent studies demonstrated that mutant KRAS generates immunogenic neoantigens that are targetable by adoptive T‐cell therapy in metastatic diseases. To expand …

gb, us (code pays fourni par la source)

HLA-E-VL9 antibodies enhance NK cell and CD8 + T cell cytotoxicity against HIV-infected CD4 + T cells

Joyce K. Hwang, Daniel J. Marston, Marina Tuyishime, Daniel Wrapp et autres

SUMMARY A major natural killer (NK) cell and CD8 + T cell checkpoint is mediated by the inhibitory receptor NKG2A/CD94 and its ligand, HLA-E complexed with 9 amino acid HLA-Ia leader sequence-derived peptides termed VL9 (HLA-E-VL9). Here, we used structure-based design and …

us, gb (code pays fourni par la source)

Author response for "Identification and structural characterization of a mutant KRAS‐G12V specific TCR restricted by HLA‐A3"

Malcolm J. W. Sim, Ken‐ichi Hanada, Zachary Stotz, Zhiya Yu et autres

Author response for "Identification and structural characterization of a mutant KRAS‐G12V specific TCR restricted by HLA‐A3"

Malcolm J. W. Sim, Ken‐ichi Hanada, Zachary Stotz, Zhiya Yu et autres

Identification and Structural Characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3

Malcolm J. W. Sim, Ken‐ichi Hanada, Zachary Stotz, Zhiya Yu et autres

Summary Mutations in KRAS are some of the most common across multiple cancer types and are thus attractive targets for therapy. Recent studies demonstrated that mutant KRAS generates immunogenic neoantigens that can be targeted in adoptive T cell therapy in metastatic diseases. …

gb, de (code pays fourni par la source)

Publisher Correction: High-throughput characterization of HLA-E-presented CD94/NKG2x ligands reveals peptides which modulate NK cell activation

Brooke D. Huisman, Ning Guan, Timo Rückert, Lee I. Garner et autres

The original version of this Article contained an error in Fig. 4, in which several datapoints did not display. This has been corrected in both the PDF and HTML versions of the Article.

us, de, gb (code pays fourni par la source)